Our present results suggest that the level of the sIL-18Rα complex in serum has potential clinical application as a biomarker for the diagnosis or differential diagnosis of RA or for the evaluation of disease activity in RA patients treated with TNF inhibitors. This evidence concerns the gene TNF and rheumatoid arthritis.